- Details
- Alicia Morgans and Tanya Dorff, discuss the updates to the NCCN guidelines since the approval of PSMA PET CT molecular imaging agents. They discuss new guidance based on the FDA-approved indications in the labels for the use of molecular imaging agents for detecting prostate cancer when PSA levels are still relatively low and when PSA levels are rising. Biographies: Tanya B. Dorff, MD., is an asso...
|
- Details
- Neil Bander joins Alicia Morgans in a conversation on the history of radiopharmaceuticals, their development, and where they may ultimately fit in the prostate cancer treatment landscape. Dr. Bander reviewed how these agents were developed starting roughly 18 - 20 years ago targeting PSMA with the antibody developed at Cornell, called J591, the first antibody to the extracellular domain of PSMA. H...
|
- Details
- Kosj Yamoah joins Alicia Morgans in discussing improving health equity, reducing disparities in prostate cancer care, and how the Prostate Cancer Foundation (PCF) supports this initiative. There are differences in the way prostate cancer inequity occurs, directly from the incidence, the development of the disease itself, the presentation of the disease when a patient is seen in the clinic, the res...
|
- Details
- Oliver Sartor joins Alicia Morgans and discusses the evolving landscape of BiTE ® technology applied to prostate cancer therapy. BiTE is a bispecific T-cell engaging antibody that binds on PSMA and CD3 on the T cells to activate the T cells. Bispecific T-cell engagers are a novel approach to tumor immunotherapy. They discuss the current clinical trials landscape and what is maybe on the horizon fo...
|
- Details
- In this UroToday discussion, Christina Dieli-Conwright joins Alicia Morgans in a conversation on exercise for patients and the future of exercise research for men with prostate cancer. The conversation begins with Dr. Dieli-Conwright reviewing the evidence we have to date that supports exercise for improving quality of life and mental health. She highlights the multifactorial benefits of exercise...
|
- Details
- Amina Zoubeidi joins Alicia Morgans in a conversation on the evolution of her career and how the Prostate Cancer Foundation (The PCF) played a pivotal role in supporting her research initiatives and the collaboration and friendships that result from the Women in Science Program at the PCF Annual Retreat. PCF consistently demonstrates a commitment to women scientists by supporting their research. T...
|
- Details
- Lorelei Mucci joins Alicia Morgans in a conversation on exercise and nutrition in cancer care. Dr. Mucci provides an overview of the impact of lifestyle and nutrition on cancer and disease risk. She highlights specific types of dietary patterns that are associated with a lower risk of cancer overall, specifically more aggressive forms of prostate cancer or cancers that ultimately will become fatal...
|
- Details
- Shahneen Sandhu joins Alicia Morgans in a conversation about targeted radioligand therapy in prostate cancer. They discuss several upcoming and ongoing trials with Lutetium. Biographies: Shahneen Sandhu, MD, Ph.D., MBBS, FRACP, Associate Professor, Consultant Medical Oncologist and Researcher, Peter MacCallum Cancer Centre, Melbourne, Australia Alicia Morgans, MD, MPH , Genitourinary Medical Oncol...
|
- Details
- Alicia Morgans and Tanya Dorff discuss the recent work on Bi-specific T-Cell antibody (BiTE) therapies. AMG160 is a half-life extended PSMA-targeted bispecific T-cell engager immune therapy for metastatic castration-resistant prostate cancer (mCRPC). Dr. Dorff describes BiTE therapies and the AMG 160 trial. She shares PSA responses seen in patients on BiTE therapy. Dr. Dorff discusses the adverse...
|
